文献速递淋巴瘤造血干细胞移植与细胞治疗

异体CD19 CAR-T疗法CTX110治疗复发难治B细胞非霍奇金淋巴瘤的安全性与疗效

Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.
PubMed 文献 · Blood Adv · 2026-01-01

这项多中心单臂1/2期研究评估了异体CD19 CAR-T疗法CTX110在复发难治B细胞非霍奇金淋巴瘤成人患者中的安全性和疗效。患者接受1或2个疗程治疗,剂量递增组32例,队列扩展组31例。CTX110耐受性良好,在DL≥3时产生有临床意义的缓解,第二次输注显示进一步临床获益。

要点

  • CTX110在DL≥3时客观缓解率65%,完全缓解率39%。
  • 两次输注方案较单次输注延长缓解持续时间(HR 0.65)。
  • CRS发生率54%,ICANS发生率13%,严重不良事件发生率32%。

核心结论

  • 在复发难治B细胞非霍奇金淋巴瘤患者中,CTX110耐受性良好,在DL≥3时产生有临床意义的缓解,第二次输注显示进一步临床获益。

研究设计与样本

  • 多中心、单臂、1/2期研究,纳入63例重度经治的复发难治B细胞非霍奇金淋巴瘤成人患者。
  • 剂量递增组32例接受1次CTX110输注(DL1-4,3×10^7至60×10^7 CAR T细胞),队列扩展组31例在DL4于第1天和第35天接受2次输注。
  • 剂量递增主要终点为剂量限制性毒性发生率,队列扩展主要终点为客观缓解率。

主要发现

  • 63例接受CTX110治疗的患者中,59%为原发难治,43%既往接受≥3线治疗。
  • 首次输注DL≥3的57例患者中,客观缓解率和完全缓解率分别为65%和39%。
  • 22例达到完全缓解的患者中,5例(23%)在数据截止时仍持续完全缓解,随访15至50个月(中位34个月)。
  • 两次输注方案较单次输注延长缓解持续时间(风险比0.65)。
  • CRS和ICANS分别发生于54%和13%的治疗患者,各包括2例≥3级事件;最常见≥3级不良事件为中性粒细胞减少(59%)、贫血和血小板减少(各35%)。

临床怎么用

  • 对于重度经治的复发难治B细胞非霍奇金淋巴瘤,异体CD19 CAR-T CTX110在DL≥3时可考虑作为治疗选择。
  • 采用两次输注方案可能延长缓解持续时间。
  • 治疗中需重点监测CRS、ICANS及中性粒细胞减少、贫血、血小板减少等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This multicenter, single-arm, phase 1/2 study evaluated the safety and efficacy of CD19-directed allogeneic chimeric antigen receptor (CAR) immunotherapy CTX110 in adult patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Patients received 1 or 2 treatment courses: standard lymphodepletion, followed by 1 CTX110 infusion at dose levels (DLs) 1 to 4 (3 × 107 to 60 × 107 CAR T cells; dose escalation, N = 32), or 2 infusions at DL4 on days 1 and 35 (cohort expansion, N = 31). Primary end points in dose escalation and cohort expansion were incidence of dose-limiting toxicities and objective response rate, respectively. CTX110 was administered to 63 heavily pretreated patients: 59% primary refractory, 43% with ≥3 previous therapies. Among 57 patients whose first infusion was DL ≥3, rates of objective and complete response (CR) were 65% and 39%, respectively. Among 22 patients achieving CR, 5 (23%) had ongoing CR at data cutoff, with 15 to 50 (median 34) months follow-up. The 2-infusion regimen prolonged response duration vs 1 infusion (hazard ratio, 0.65). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were reported in 54% and 13% of treated patients, respectively, including 2 grade ≥3 cases each. The most common grade ≥3 adverse events (AEs) were neutropenia (59%), and anemia and thrombocytopenia (35% each). Serious AEs occurred in 32% of treated patients, including CRS (14%), ICANS (8%), and febrile neutropenia (6%). In this R/R NHL population, CTX110 was well tolerated, resulting in clinically meaningful responses at DL ≥3, with a second infusion demonstrating further clinical benefit. This trial was registered at www.clinicaltrials.gov as #NCT04035434.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. McGuirk JP, Ghobadi A, Bachier CR, et al. Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood Adv. 2026. PMID: 42085626. doi:10.1182/bloodadvances.2026020123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。